NASDAQ:GELS Gelteq (GELS) Stock Price, News & Analysis $1.05 -0.04 (-3.24%) As of 03/28/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsOwnershipSEC FilingsTrendsBuy This Stock About Gelteq Stock (NASDAQ:GELS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Gelteq alerts:Sign Up Key Stats Today's Range$0.95▼$1.1150-Day Range$0.98▼$2.8952-Week Range$0.95▼$5.50Volume75,623 shsAverage Volume175,365 shsMarket Capitalization$9.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.Read More… Remove Ads Receive GELS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gelteq and its competitors with MarketBeat's FREE daily newsletter. Email Address GELS Stock News HeadlinesGelteq Limited Secures $12 Million Funding Agreement with Lincoln ParkMarch 14, 2025 | tipranks.comGelteq's Sportsgel Brand Named Official Sponsor of the Professional Pickleball Tour and League of Australia and New ZealandFebruary 27, 2025 | globenewswire.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. March 29, 2025 | Porter & Company (Ad)Gelteq Appoints Matthew Jones as Head of Sports PerformanceJanuary 24, 2025 | globenewswire.comGelteq Receives FDA Approval of its Suitability Petition for New Animal DrugDecember 17, 2024 | globenewswire.comGelteq to Participate in the Benchmark Company 13th Annual Discovery Investor ConferenceDecember 9, 2024 | globenewswire.comGelteq Limited Announces 50% Increase in Order from Healthy Extracts Amid Growing Demand for Gel-Based NutraceuticalsDecember 2, 2024 | quiverquant.comGelteq Announces Largest U.S. Customer Increases Initial Order by 50% to Meet Growing Market DemandDecember 2, 2024 | globenewswire.comSee More Headlines GELS Stock Analysis - Frequently Asked Questions How have GELS shares performed this year? Gelteq's stock was trading at $2.32 on January 1st, 2025. Since then, GELS stock has decreased by 54.7% and is now trading at $1.05. View the best growth stocks for 2025 here. When did Gelteq IPO? Gelteq (GELS) raised $5 million in an initial public offering (IPO) on Tuesday, October 29th 2024. The company issued 1,300,000 shares at $4.00 per share. The Benchmark Company served as the underwriter for the IPO. When does the company's lock-up period expire? Gelteq's lock-up period expires on Monday, April 28th. Gelteq had issued 1,300,000 shares in its IPO on October 29th. The total size of the offering was $5,200,000 based on an initial share price of $4.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period. Who are Gelteq's major shareholders? Top institutional investors of Gelteq include Citadel Advisors LLC (0.25%). How do I buy shares of Gelteq? Shares of GELS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today3/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GELS Previous SymbolNASDAQ:GELS CIK1920092 Webwww.gelteq.com Phone61-3-9087-3990FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares9,438,000Free FloatN/AMarket Cap$9.91 million OptionableN/A BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:GELS) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.